Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Association of Abdominal Arterial Calcification Score with Patients’ Survival and Kidney Allograft Function after Kidney Transplant
Jarmi, Tambi , Spaulding, Aaron , Jebrini, Abdullah, Sella, David M., Alexander, Lauren F. , Nussbaum, Samuel R., Shoukry, Mira , White, Launia J. , Wadei, Hani M. , Farres, Houssam , Spaulding, Aaron C. , Nussbaum, Samuel , White, Launia, Spaulding, Aaron , Alexander, Lauren F , Wadei, Hani M , Jarmi, Tambi , Nussbaum, Samuel

Mayo Clinic

World Journal of Surgery | July 19, 2022 | Volume: 46 | Issue: 10 | Pages: 2468-2475

10.1007/s00268-022-06665-z | PMID 35854013 Get It

AbstractBackgroundAbdominal arterial calcification (AAC) is common among candidates for kidney transplant. The aim of this study is to correlate AAC score value with post‐kidney transplant outcomes.MethodsWe modified the coronary calcium score by changing the intake data points and used it to quantitate the AAC. We conducted a retrospective clinical study of all adult patients who were transplanted at our center, between 2010 and 2013, and had abdominal computed tomography scan done before transplantation. Outcomes included mortality, pulse pressure (PP) measured by 24 h ambulatory blood pressure monitoring system, and kidney allograft function measured by iothalamate clearance.ResultsFor each 1000 increase of AAC score value, there is an associated 1.05 increase in the risk of death (95% CI 1.02, 1.08) (p < 0.001). Overall median AAC value for all patients was 1784; Kaplan–Meier curve showed reduced survival of all‐cause mortality for patients with AAC score value above median and reduced survival among patients with cardiac related mortality. The iothalamate clearance was lower among patients with total AAC score value above the median. Patients with abnormal PP (< 40 or > 60 mmHg) had an elevated median AAC score value at 4319.3 (IQR 1210.4, 11097.1) compared to patients with normal PP with AAC score value at 595.9 (IQR 9.9, 2959.9) (p < 0.001).ConclusionWe showed an association of AAC with patients’ survival and kidney allograft function after kidney transplant. The AAC score value could be used as a risk stratification when patients are considered for kidney transplant.
Venetoclax Plus Gilteritinib for FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia
Daver, Naval , Perl, Alexander E. , Maly, Joseph, Ritchie, Ellen K. , Litzow, Mark R. , McCloskey, James, Smith, Catherine C. , Schiller, Gary J. , Bradley, Terrence, Tiu, Ramón V., Naqvi, Kiran , Brackman, Deanna J. , Siddani, Satya R., Wang, Jing , Chyla, Brenda , Lee, Paul , Altman, Jessica K. , Litzow, Mark R. , Smith, Catherine C , Dail, Monique , Chyla, Brenda , Altman, Jessica K , Daver, Naval , Levis, Mark J. , Dail, Monique

Mayo Clinic

Journal of Clinical Oncology | July 18, 2022 | Volume: 40 | Issue: 35 | Pages: 4048-4059

10.1200/jco.22.00602 | PMID 35849791 Get It

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated ( FLT3 mut ) acute myeloid leukemia (AML) but seldom reduces FLT3 mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetoclax in preclinical models of FLT3 mut AML. METHODS This phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505 ) enrolled patients with FLT3 wild-type and FLT3 mut (escalation) or FLT3 mut (expansion) relapsed/refractory AML. Patients received 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The primary objectives were safety, identification of the recommended phase II dose, and the modified composite complete response (mCRc) rate (complete response [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery + morphologic leukemia-free state) using ADMIRAL phase III–defined response criteria. RESULTS Sixty-one patients were enrolled (n = 56 FLT3 mut ); 64% (n = 36 of 56) of FLT3 mut patients had received prior FLT3 inhibitor therapy. The recommended phase II dose was 400 mg venetoclax once daily and 120 mg gilteritinib once daily. The most common grade 3/4 adverse events were cytopenias (n = 49; 80%). Adverse events prompted venetoclax and gilteritinib dose interruptions in 51% and 48%, respectively. The mCRc rate for FLT3 mut patients was 75% (CR, 18%; CR with incomplete blood count recovery, 4%; CR with incomplete platelet recovery, 18%; and morphologic leukemia-free state, 36%) and was similar among patients with or without prior FLT3 inhibitor therapy (80% v 67%, respectively). The median follow-up was 17.5 months. The median time to response was 0.9 months, and the median remission duration was 4.9 months (95% CI, 3.4 to 6.6). FLT3 molecular response (< 10 −2 ) was achieved in 60% of evaluable mCRc patients (n = 15 of 25). The median overall survival for FLT3 mut patients was 10.0 months. CONCLUSION The combination of venetoclax and gilteritinib was associated with high mCRc and FLT3 molecular response rates regardless of prior FLT3 inhibitor exposure. Dose interruptions were needed to mitigate myelosuppression.
Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter’s Trans-Formed DLBCL and Germinal Center B-Cells
Uhl, Barbara , Pansy, Katrin , Wenzl, Kerstin , Strobl, Johanna , Baumgartner, Claudia , Szmyra, Marta , Waha, James Elvis, Wolf, Axel , Tomazic, Peter Valentin , Steinbauer, Elisabeth, Steinwender, Maria, Friedl, Sabine, Weniger, Marc A., Küppers, Ralf , Pichler, Martin , Greinix, Hildegard , Ramsay, Alan G. , Apollonio, Benedetta , Feichtinger, Julia , Beham‐Schmid, Christine, Neumeister, Peter , Deutsch, Alexander , Pansy, Katrin , Strobl, Johanna , Küppers, Ralf , Pichler, Martin , Ramsay, Alan G , Feichtinger, Julia , Deutsch, Alexander J , Prochazka, Katharina Theresa , Baumgartner, Claudia, Stary, Georg

Mayo Clinic

International Journal of Molecular Sciences | July 17, 2022 | Volume: 23 | Issue: 14 | Pages: 7874

10.3390/ijms23147874 | PMID 35887224 Get It

Chemokine receptors and their ligands have been identified as playing an important role in the development of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and Richter syndrome (RS). Our aim was to investigate the different expression profiles in de novo DLBCL, transformed follicular lymphoma (tFL), and RS. Here, we profiled the mRNA expression levels of 18 chemokine receptors (CCR1–CCR9, CXCR1–CXCR7, CX3CR1 and XCR1) using RQ-PCR, as well as immunohistochemistry of seven chemokine receptors (CCR1, CCR4–CCR8 and CXCR2) in RS, de novo DLBCL, and tFL biopsy-derived tissues. Tonsil-derived germinal center B-cells (GC-B) served as non-neoplastic controls. The chemokine receptor expression profiles of de novo DLBCL and tFL substantially differed from those of GC-B, with at least 5-fold higher expression of 15 out of the 18 investigated chemokine receptors (CCR1–CCR9, CXCR1, CXCR2, CXCR6, CXCR7, CX3CR1 and XCR1) in these lymphoma subtypes. Interestingly, the de novo DLBCL and tFL exhibited at least 22-fold higher expression of CCR1, CCR5, CCR8, and CXCR6 compared with RS, whereas no significant difference in chemokine receptor expression profile was detected when comparing de novo DLBCL with tFL. Furthermore, in de novo DLBCL and tFLs, a high expression of CCR7 was associated with a poor overall survival in our study cohort, as well as in an independent patient cohort. Our data indicate that the chemokine receptor expression profile of RS differs substantially from that of de novo DLBCL and tFL. Thus, these multiple dysregulated chemokine receptors could represent novel clinical markers as diagnostic and prognostic tools. Moreover, this study highlights the relevance of chemokine signaling crosstalk in the tumor microenvironment of aggressive lymphomas.
Descriptive Characteristics and Outcomes of Patients Undergoing Revision Anterior Cruciate Ligament Reconstruction With and Without Tunnel Bone Grafting
Group, MARS, DeFroda, Steven F. , Wright, Rick W. , Huston, Laura J. , Pennings, Jacquelyn S. , Haas, Amanda K. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Albright, John P., Amendola, Annunziato , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Bechler, Jeffery R., Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Brophy, Robert H. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Cox, Charles L. , Creighton, R. Alexander , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Garofoli, Elizabeth A. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C. , Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCarty, Eric C. , McCormack, Robert G. , Miller, Bruce S. , Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Slauterbeck, James R., Smith, Matthew V. , Spang, Jeffrey T. , Svoboda, Steven J. , Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Williams, James S., Wolcott, Michelle L., Wolf, Brian R. , York, James J. , Brophy, Robert H. , McCarty, Eric C , Group, MARS, Owens, Brett D. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J. , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Benjamin, C. , McAllister, David R. , Shea, Kevin G. , Sherman, Orrin H.

Mayo Clinic

The American Journal of Sports Medicine | July 14, 2022 | Volume: 50 | Issue: 9 | Pages: 2397-2409

10.1177/03635465221104470 | PMID 35833922 Get It

Background: Lytic or malpositioned tunnels may require bone grafting during revision anterior cruciate ligament reconstruction (rACLR) surgery. Patient characteristics and effects of grafting on outcomes after rACLR are not well described. Purpose: To describe preoperative characteristics, intraoperative findings, and 2-year outcomes for patients with rACLR undergoing bone grafting procedures compared with patients with rACLR without grafting. Study Design: Cohort study; Level of evidence, 3. Methods: A total of 1234 patients who underwent rACLR were prospectively enrolled between 2006 and 2011. Baseline revision and 2-year characteristics, surgical technique, pathology, treatment, and patient-reported outcome instruments (International Knee Documentation Committee [IKDC], Knee injury and Osteoarthritis Outcome Score [KOOS], Western Ontario and McMaster Universities Osteoarthritis Index, and Marx Activity Rating Scale [Marx]) were collected, as well as subsequent surgery information, if applicable. The chi-square and analysis of variance tests were used to compare group characteristics. Results: A total of 159 patients (13%) underwent tunnel grafting—64 (5%) patients underwent 1-stage and 95 (8%) underwent 2-stage grafting. Grafting was isolated to the femur in 31 (2.5%) patients, the tibia in 40 (3%) patients, and combined in 88 patients (7%). Baseline KOOS Quality of Life (QoL) and Marx activity scores were significantly lower in the 2-stage group compared with the no bone grafting group ( P≤ .001). Patients who required 2-stage grafting had more previous ACLRs ( P < .001) and were less likely to have received a bone–patellar tendon–bone or a soft tissue autograft at primary ACLR procedure ( P≤ .021) compared with the no bone grafting group. For current rACLR, patients undergoing either 1-stage or 2-stage bone grafting were more likely to receive a bone–patellar tendon–bone allograft ( P≤ .008) and less likely to receive a soft tissue autograft ( P≤ .003) compared with the no bone grafting group. At 2-year follow-up of 1052 (85%) patients, we found inferior outcomes in the 2-stage bone grafting group (IKDC score = 68; KOOS QoL score = 44; KOOS Sport/Recreation score = 65; and Marx activity score = 3) compared with the no bone grafting group (IKDC score = 77; KOOS QoL score = 63; KOOS Sport/Recreation score = 75; and Marx activity score = 7) ( P≤ .01). The 1-stage bone graft group did not significantly differ compared with the no bone grafting group. Conclusion: Tunnel bone grafting was performed in 13% of our rACLR cohort, with 8% undergoing 2-stage surgery. Patients treated with 2-stage grafting had inferior baseline and 2-year patient-reported outcomes and activity levels compared with patients not undergoing bone grafting. Patients treated with 1-stage grafting had similar baseline and 2-year patient-reported outcomes and activity levels compared with patients not undergoing bone grafting.
A multidisciplinary approach to the management of brachial plexus injuries: experience from the Mayo Clinic over 100 years
Shin, Alexander Y. , Loosbroch, Michelle F., Spinner, Robert J. , Shin, Alexander Y , Bishop, Allen T.

Mayo Clinic

Journal of Hand Surgery (European Volume) | July 14, 2022 | Volume: 47 | Issue: 11 | Pages: 1103-1113

10.1177/17531934221110733 | PMID 35833214 Get It

A multidisciplinary brachial plexus clinic has been a relatively new concept, offering different surgical speciality perspectives on the treatment of brachial plexus injuries. The resulting collaborative effort has proven to be greater than the sum of its parts. In this review, the history, philosophy of care, development/implementation and impact of a creation of a multidisciplinary brachial plexus team at the Mayo Clinic are detailed.
Uric Acid Expression in Carotid Atherosclerotic Plaque and Serum Uric Acid Are Associated With Cerebrovascular Events
Nardi, Valentina , Franchi, Federico , Prasad, Megha , Fatica, Erica M. , Alexander, Mariam P., Bois, Melanie C. , Lam, Josephine, Meyer, Fredric B. , Lanzino, Giuseppe , Xiong, Yuning, Lerman, Lilach O. , Lanzino, Giuseppe , Lerman, Lilach O , Nardi, Valentina , Singh, Ravinder J. , Lutgens, Esther , Lerman, Amir

Mayo Clinic

Hypertension | July 13, 2022 | Volume: 79 | Issue: 8 | Pages: 1814-1823

10.1161/hypertensionaha.122.19247 | PMID 35656807 Get It

Background: Uric acid (UA) concentration within carotid plaque and its association with cerebrovascular events have not been detected or quantified. Systemically, serum UA is a marker of inflammation and risk factor for atherosclerosis. However, its association with carotid plaque instability and stroke pathogenesis remains unclear. In patients undergoing carotid endarterectomy, we aimed to determine whether UA is present differentially in symptomatic versus asymptomatic carotid plaques and whether serum UA is associated with cerebrovascular symptoms (stroke, transient ischemic attack, or amaurosis fugax). Methods: Carotid atherosclerotic plaques were collected during carotid endarterectomy. The presence of UA was assessed using Gomori methenamine silver staining as well as anti-UA immunohistochemical staining and its quantity measured using an enzymatic colorimetric assay. Clinical information was obtained through a retrospective review of data. Results: UA was more commonly detected in symptomatic (n=23) compared with asymptomatic (n=9) carotid plaques by Gomori methenamine silver (20 [86.9%] versus 2 [22.2%]; P =0.001) and anti-UA immunohistochemistry (16 [69.5%] versus 1 [11.1%]; P =0.004). UA concentration was higher in symptomatic rather than asymptomatic plaques (25.1 [9.5] versus 17.9 [3.8] µg/g; P =0.021). Before carotid endarterectomy, serum UA levels were higher in symptomatic (n=341) compared with asymptomatic (n=146) patients (5.9 [interquartile range, 4.6–6.9] mg/dL versus 5.2 [interquartile range, 4.6–6.2] mg/dL; P =0.009). Conclusions: The current study supports a potential role of UA as a potential tissue participant and a systemic biomarker in the pathogenesis of carotid atherosclerosis. UA may provide a mechanistic explanation for plaque instability and subsequent ischemic cerebrovascular events.
Neurointerface with Oscillator Motifs for inhibitory effect over antagonist muscles for compensation of spastical syndrome
Mikhailova, Yulia, Pozdeeva, Anna, Suleimanova, Alina , Leukhin, Alexey , Lukmanov, Timur, Fatykhova, Elsa, Talanov, Max , Toschev, Alexander Sergeevich , Magid, Evgeni , Lavrov, Igor

Mayo Clinic

No container title available | July 12, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1661671/v1 Get It

Abstract The inhibitory management effect is usually un- derestimated in artificial control systems, using biological anal- ogy. According to our hypothesis, the muscle hypertonus could be effectively compensated via stimulation by bio plausible patterns. We proposed the approach for the compensatory stimulation device in development of previously presented archi- tecture of neurointerface, where (1) neuroport is implemented as DAC and stimulator, (2) neuroterminal – as neurosimulation of a set of oscillator motifs on one-board computer. In the set of experiments with 5 volunteers we measured the efficacy of motor neuron inhibition via antagonist muscle or nerve stim- ulation registering muscle force with and without antagonist stimulation. For the agonist activation, we used both voluntary activity and electrical stimulation. In the case of stimulation of both agonist and antagonist muscles and nerves, we exper- imented with delays between muscles stimulation starts in the range 0...20 ms. We registered the subjective discomfort rate. We didn’t identify a significant difference between antagonist muscle and nerve stimulation in both voluntary and stimulation of agonist activity. We determined the most effective delay between stimulation of agonist and antagonist muscle/nerve as 10–20 ms.
The Interaction between HLA‐DRB1 and Smoking in Parkinson's Disease Revisited
Domenighetti, Cloé , Douillard, Venceslas , Sreelatha, Ashwin Ashok Kumar , Schulte, Claudia , Grover, Sandeep , May, Patrick , Radivojkov‐Blagojevic, Milena , Lichtner, Peter , Singleton, Andrew B., Hernandez, Dena G., Edsall, Connor , Mellick, George D. , Zimprich, Alexander , Pirker, Walter , Kõks, Sulev, Lesage, Suzanne , Chartier‐Harlin, Marie‐Christine , Brockmann, Kathrin , Deutschländer, Angela , Hadjigeorgiou, G., Dardiotis, Efthimos, Simitsi, Athina Maria, Petrucci, Simona , Straniero, Letizia , Pezzoli, Gianni , Brighina, Laura , Ferrarese, Carlo , Annesi, Grazia , Quattrone, Andrea , Gagliardi, Monica , Nakayama, Akiyoshi , Kim, Yun Joong , Kolber, Pierre, Warrenburg, Bart P.C. van de , Bloem, Bastiaan R. , Aasly, Jan , Toft, Mathias , Guedes, Leonor Correia , Ferreira, Joaquim J. , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Pástor, Pau , Wirdefeldt, Karin , Ran, Caroline , Puschmann, Andreas , Ygland, Emil , Morrison, Karen , Krainc, Dimitri, Burbulla, Lena F. , Krüger, Rejko , Gasser, Thomas , Sharma, Manu , Vince, Nicolas , Elbaz, Alexis , Schulte, Claudia , Grover, Sandeep , May, Patrick , Bobbili, Dheeraj R , Corvol, Jean-Christophe , Mutez, Eugénie , Brockman, Kathrin , Valente, Enza Maria , Toft, Mathias , Ferreira, Joaquim J , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Tan, Manuela , Sharma, Manu , Elbaz, Alexis , Puschmann, Andreas , Zimprich, Alexander , Pastor, Pau , Koks, Sulev , Domenighetti, Cloé , Sugier, Pierre‐Emmanuel , Bobbili, Dheeraj Reddy , Singleton, Andrew , Gourraud, Pierre‐Antoine , Rogaeva, Ekaterina A. , Lang, Anthony E. , Taba, Pille , Brice, Alexis , Corvol, Jean‐Christophe , Mutez, Eugénie , Stefanis, Leonidas , Simitsi, Athina‐Maria , Valente, Enza Maria , Duga, Stefano , Zecchinelli, Anna , Matsuo, Hirotaka , Hattori, Nobutaka , Nishioka, Kenya , Chung, Sun Ju , Pihlstrøm, Lasse , Carr, Jonathan , Díez-Fairén, Mónica , Pedersen, Nancy L. , Belin, Andrea Carmine , Clarke, Carl E , Krainc, Dimitri , Farrer, Matthew J.

Mayo Clinic

Movement Disorders | July 10, 2022 | Volume: 37 | Issue: 9 | Pages: 1929-1937

10.1002/mds.29133 | PMID 35810454 Get It

AbstractBackgroundTwo studies that examined the interaction between HLA‐DRB1 and smoking in Parkinson's disease (PD) yielded findings in opposite directions.ObjectiveTo perform a large‐scale independent replication of the HLA‐DRB1 × smoking interaction.MethodsWe genotyped 182 single nucleotide polymorphism (SNPs) associated with smoking initiation in 12 424 cases and 9480 controls to perform a Mendelian randomization (MR) analysis in strata defined by HLA‐DRB1.ResultsAt the amino acid level, a valine at position 11 (V11) in HLA‐DRB1 displayed the strongest association with PD. MR showed an inverse association between genetically predicted smoking initiation and PD only in absence of V11 (odds ratio, 0.74, 95% confidence interval, 0.59–0.93, PInteraction = 0.028). In silico predictions of the influence of V11 and smoking‐induced modifications of α‐synuclein on binding affinity showed findings consistent with this interaction pattern.ConclusionsDespite being one of the most robust findings in PD research, the mechanisms underlying the inverse association between smoking and PD remain unknown. Our findings may help better understand this association. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Histologic response to steroids in eosinophilic esophagitis is dependent on delivery compound
Schupack, Daniel , Johnson, Kimberly R. , Akambase, Joseph , Geno, Debra M., Lavey, Crystal, Lennon, Ryan J. , Snyder, Diana L. , Katzka, David A. , Alexander, Jeffrey A. , Schupack, D , Johnson, Kimberly , Akambase, Joseph A , Geno, Debra, Ravi, Karthik

Mayo Clinic

Diseases of the Esophagus | July 3, 2022 | Volume: 36 | Issue: 1 | Pages: No page available

10.1093/dote/doac040 | PMID 35780320 Get It

Summary Topical steroids are commonly used in treatment of eosinophilic esophagitis (EoE), but currently there is lack of data to clarify most effective regimen. We aimed to study the achievement of histologic remission using the same dose of budesonide in two different delivery formulations. Patients with established EoE treated with pharmacy compounded budesonide capsule or budesonide Rincinol gel (both 3 mg twice daily) were studied retrospectively. Those with pre-treatment and post-treatment histologic assessment were included with main endpoint being histologic remission. 103 patients (62 gel, 41 capsule) were included, with higher rate of histologic remission with gel (84 vs. 59%, P=0.004). A subset of patients in both groups had lack of steroid response (&lt;50% drop in eosinophils) (15% for gel, 32% for capsule). Formulation/delivery vehicle of steroid treatments to esophageal mucosa in EoE appears important for treatment efficacy, with budesonide gel having higher likelihood of histologic remission compared to budesonide capsules in our population. A truly steroid refractory group appears likely in our population. Larger, prospective studies may help clarify best regimen of topical steroids in EoE and may work to identify patients likely to benefit from alternative therapies.
Cardiac Implantable Electronic Devices in Ebstein Anomaly: Management and Outcomes
Tan, Nicholas Y. , Amin, Mustapha, McLeod, Christopher J. , Stephens, Elizabeth H. , Cannon, Bryan C. , Miranda, William R. , Connolly, Heidi M. , Egbe, Alexander C. , Asirvatham, Samuel J. , Madhavan, Malini , McLeod, Christopher J , Stephens, Elizabeth H , Miranda, William R , Connolly, Heidi M , Egbe, Alexander C , Asirvatham, Samuel J , Madhavan, Malini , Dearani, Joseph A.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | June 28, 2022 | Volume: 15 | Issue: 7 | Pages: No page available

10.1161/circep.121.010744 | PMID 35763435 Get It

Background: Optimal management of cardiac implantable electronic devices (CIEDs) in patients with Ebstein anomaly during tricuspid valve (TV) surgery is unknown. Thus, we aimed to characterize CIED management/outcomes in patients with Ebstein anomaly undergoing TV surgery. Methods: Patients at the Mayo Clinic from 1987 to 2020 with Ebstein anomaly and CIED procedure were reviewed for procedural details, complications, echocardiogram, and lead parameters. Five-year cumulative incidence of CIED complications were estimated using the Kaplan-Meier method. Results: Ninety-three patients were included; 51 were female, and mean age was 40.7±17.5 years. A new CIED was implanted in 45 patients at the time of TV surgery with the majority receiving an epicardial (n=37) CIED. Among 34 patients who had preexisting CIED (11 epicardial, 23 transvenous) at time of TV surgery, 20 had a transvenous right ventricular lead managed by externalizing the lead to the TV (n=15) or extracting the transvenous lead with epicardial lead implantation (n=5). Fourteen patients underwent CIED implantation (4 epicardial, 10 transvenous) without concurrent surgery. Placement of lead across the TV was avoided in 85% of patients. The 5-year cumulative incidence of CIED complications was 24% with no significant difference between epicardial and transvenous CIEDs (26% versus 23%, P =0.96). Performance of lead parameters was similar in epicardial and transvenous leads during median (interquartile range) follow-up of 44.5 (61.1) months. Conclusions: In patients with Ebstein anomaly undergoing TV surgery, the use of epicardial leads and externalization of transvenous leads to the TV can avoid lead placement across the valve leaflets. Lead performance and CIED complications was similar between epicardial and transvenous CIEDs.